Drug Profile
VBP 926
Alternative Names: Povidone iodine; VBP-926Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Veloce BioPharma
- Class Antiseptics; Disinfectants; Pyrrolidinones; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pachyonychia congenita
Most Recent Events
- 22 Oct 2020 No development reported - Phase-II for Pachyonychia congenita in USA (Topical)
- 03 Oct 2018 Efficacy and adverse events data from a phase IIb trial in Paronychia (chemotherapy-associated) released by Veloce BioPharma
- 03 Oct 2018 Veloce BioPharma plans a phase III clinical trial in Paronychia (chemotherapy associated)